3D Executive Search Partners’ Post

IRLAB Therapeutics AB In our recent analysis conducted with EQL desktop, we have reviewed IRLAB Therapeutics AB, a biopharmaceutical company based in Gothenburg, Sweden. Current Developments: IRLAB's development pipeline includes Mesdopetam in phase IIb/III trials for dyskinesia in Parkinson’s disease and several preclinical initiatives aimed at neurodegenerative disorders. Strategic Approach: Our research provides an objective look into IRLAB’s strategic methods and the progress of their clinical trials, presenting a clear picture of their operations and potential implications for patient care. Sign up today: https://lnkd.in/dJ8zhDrP #ResearchwithAI #EQL #Irlab #marketintelligence

Day 1: Working on #oligonucleotide-based therapies? Connect with our WuXi TIDES team at the 9th OPT Congress in Boston from March 13-14. On March 13 at 12:45 pm EST, Yvonne Angell, Ph.D., our Executive Director and Head of TIDES discovery project management, will outline the technical challenges encountered in the discovery phase of oligonucleotide therapeutics. Through two case studies, we’ll detail our strategies for advancing programs from discovery to development, addressing technical obstacles and optimizing our approach. This presentation will offer practical insights for navigating the complexities of oligonucleotide therapy development.   Schedule a meeting with our team: WuXi_TIDES@wuxiapptec.com Learn more: https://lnkd.in/g6AmChYd #WuXiTIDES #peptides #oligonucleotides #CRDMO

Here’s why you can’t miss out on the upcoming 5th Dry AMD & GA Therapeutics Summit: 💡What is the 5th Dry AMD & GA Therapeutics Summit? A key industry-centric meeting devoted to revolutionizing earlier intervention and reduced administration frequency of more efficacious and safer dry AMD & GA drugs 💡Why attend? Gain valuable insights from 20+ speakers as they delve into discovering faster biomarkers and functional endpoints, new in vitro and in vivo preclinical models, less invasive and accurate delivery routes, optimizing phase 1 clinical trials, and more 💡Who’s going? Industry leaders from ophthalmic departments such as Apellis Pharmaceuticals, Sanofi, Boehringer Ingelheim, Aviceda Therapeutics, AbbVie, ONL Therapeutics, GelMEDIX, Beacon Therapeutics, Nanoscope Therapeutics Inc., Genentech and more Find out more: https://ter.li/m16oxi

🚀 Kicking off Day 2 of the 20th BioPharma Drug Discovery Nexus Conference with a bang! Join Mauro Mileni Founder and CEO, Abilita Therapeutics, Inc. as he unveils insights into 'Enabling the Discovery of Therapeutic Antibodies Targeting Challenging Membrane Proteins'. Don't miss out on this enlightening session! #BioPharma #DrugDiscovery #Innovation #Antibodies #Therapeutics #Membraneproteins #Epitopes #Conformational #Protiens #NexusConference #SanDiego #USconference #ScientificConference

Fibromyalgia Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | AppliedVR, Aptinyx, Scilex Holding, Tryp Therapeutics, UCB, Virios Therapeutics, Axsome Therapeutics, Paradise Genomics, Tonix Pharma https://lnkd.in/ezgz92_r #marketanalysis #marketresearch #marketresearchreports #businessintelligence

DelveInsight Business Research LLP's EHA 2024 post-conference analysis on Multiple Myeloma focuses on industry sponsored & high priority trial data. With more than 28 abstracts in different multiple myeloma settings were presented at the EHA meeting this year. Johnson & Johnson presented more than 8 most anticipated abstracts, while Bristol Myers Squibb and Sanofi presented more than 3 important abstracts for multiple myeloma. Other key players which presented their insights on Multiple Myeloma at the EHA 2024 Conference include Takeda, Regeneron, Gracell Biotechnologies, IASO BioTherapeutics（驯鹿生物）, CARsgen Therapeutics, Roche, GSK, Pfizer, BeiGene, Karyopharm Therapeutics Inc., Ascentage Pharma, and AbbVie. Unlock In-Depth European Hematology Association (EHA) 2024 conference insights @ https://lnkd.in/gWc25art Comment below to get a detailed EHA 2024 post-conference analysis!

Lisata Therapeutics, Inc. presentation by Dr. David J. Mazzo, Ph.D., President & CEO at the 10th Annual Oncology Innovation Forum Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s lead product candidate, certepetide (formerly LSTA1), is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform® technology. The Company expects to announce numerous milestones over the next two years and believes that its projected capital will fund operations into early 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. View here: https://lnkd.in/dDkhmGte

Innovation in IBD Treatment: Ensho Therapeutics' Promising Journey 🚀 Breaking new ground in the fight against IBD, Ensho Therapeutics acquires a transformative suite of α4β7 integrin inhibitors from EA Pharma. With NSHO-101 taking the lead, this phase 2-ready clinical program offers hope for those battling ulcerative colitis. The current landscape lacks orally administered α4β7 inhibitors, so this deal could revolutionize treatment for patients. Given the success of similar biologics like Entyvio, the potential of Ensho's portfolio is hard to ignore. Leveraging a successful phase 1 trial, the anticipation for phase 2 is palpable. The seamless collaboration with EA Pharma fuels Ensho's mission to provide a new therapeutic avenue where others fall short. What strikes me is Ensho's commitment, evident in the expert team they've assembled. With names like Bitritto-Garg at the helm and Bittoo Kanwar stepping in soon, their collective experience signals a bold new era in IBD therapy! #HealthcareInnovation #IBDTreatment #BiotechIndustry

Neurogenic Detrusor Overactivity Treatment Market Size in the 7MM is expected to witness a major change in the study period 2020-2034: Neurogenic Detrusor Overactivity Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Neurogenic Detrusor Overactivity Therapeutics includes promising candidates that aim … Continue reading → #PharmaceuticalsBiotech

This week's top #pharma news stories...https://lnkd.in/dzZtC_35 1. Merck's #Keytruda grabs third #cervicalcancer OK, but with limited scope 2. FDA approves #Casgevy from Vertex Pharmaceuticals and CRISPR Therapeutics for beta thalassaemia 3. Daiichi Sankyo gains momentum in #ADC space, with ifinatamab deruxtecan entering late stage amidst patent battle win 4. GSK to score $1.3B in third Haleon stake sale 5. Roche’s Phase III win for #tiragolumab leaves study design questions #biopharma #biotechnology #cancer #clinicalresearch #clinicaltrials #drugdevelopment #medicalaffairs #mergersandacquisitions #pharmaceuticals #regulatoryaffairs